Versant Capital Management, Inc Ultragenyx Pharmaceutical Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 304 shares of RARE stock, worth $8,545. This represents 0.0% of its overall portfolio holdings.
Number of Shares
304
Previous 174
74.71%
Holding current value
$8,545
Previous $6,000
83.33%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RARE
# of Institutions
342Shares Held
90.2MCall Options Held
1.03MPut Options Held
1.04M-
Vanguard Group Inc Valley Forge, PA10.2MShares$287 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$158 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$111 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$90.5 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$73.6 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.97B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...